Blephamide — Class II drug recall D-0929-2017
Terminated recall by Allergan Sales, LLC, reported 2017-07-05, distributed nationwide. Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for imp
| Recall number | D-0929-2017 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Allergan Sales, LLC, Waco, TX, United States |
| Recall initiated | 2017-05-01 |
| Classified | 2017-06-29 |
| Reported by FDA | 2017-07-05 |
| Terminated | 2019-05-01 |
| Distributed | Nationwide (US) |
| Quantity | 648 units |
| Reason classes | specification failure |
| NDC | 00023-0313-04 |
| Lot numbers | 93802 |
| Expiration dates | 2019-11-20 |
Product
Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.
Reason for recall
Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0929-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.